• Galectin Therapeutics Chief Medical Officer Jamil Khurram sold 52,037 common shares on June 26-29 at weighted-average prices of $5 and $5.04.
• Sales followed option exercises at $2.2 to $2.5, leaving him with 0 common shares directly owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001133416-26-000059), on June 30, 2026, and is solely responsible for the information contained therein.